← Patent-cliff monitor small molecule JAKAFI RUXOLITINIB PHOSPHATE
Loss of exclusivity March 2029 FDA regulatory exclusivity expiry
Company Incyte → See this company's full patent-cliff portfolio Drug detail Brand name JAKAFI Active ingredient RUXOLITINIB PHOSPHATE Strength EQ 25MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval November 2011 Marketing status RX
Listed patents Patent Expires Type 10016429*PED December 2028 — 8722693*PED December 2028 — 8829013*PED December 2028 — 8822481*PED December 2028 — 7598257*PED June 2028 — 8415362*PED June 2028 — 8822481 June 2028 use U-3230 8829013 June 2028 use U-3227 10016429 June 2028 use U-3230 8722693 June 2028 substance, product 8415362 December 2027 substance, product 7598257 December 2027 substance, product 9079912*PED June 2027 — 9814722*PED June 2027 — 9814722 December 2026 use U-3230 9079912 December 2026 use U-3230
Regulatory exclusivity Code Expires PED March 2029 ODE-373 September 2028 PED November 2026 PED June 2026 ODE-238 May 2026 M-285 December 2025
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.